Best practices in multiple sclerosis: Infusion reactions versus hypersensitivity associated with biologic therapies

Journal of Infusion Nursing

Volumn 33, Issue 2, 2010, Pages 98-111

  Namey, Marie ^a   Halper, June ^b   O'Leary, Shirley ^c   Beavin, Jill ^d   Bishop, Cynthia ^e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b The Consortium of Multiple Sclerosis Centers   (United States)

^c Multiple Sclerosis Center at Texas Neurology   (United States)

^d Raleigh Neurology Associates   (United States)

^e Multiple Sclerosis Center of Atlanta   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTHRACYCLINE; BETA1A INTERFERON; DIPHENHYDRAMINE; ETOPOSIDE; GLATIRAMER; HYDROCORTISONE; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISONE; STEROID;

ALOPECIA; ANAPHYLAXIS; ARTHRALGIA; ASTHENIA; CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; DYSPNEA; FEVER; FLUSHING; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; INJECTION SITE REACTION; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; NAUSEA; NERVOUS SYSTEM INJURY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PRIORITY JOURNAL; PRURITUS; RASH; RELAPSE; REVIEW; RIGOR; SIDE EFFECT; SJOEGREN SYNDROME; SUICIDAL IDEATION; THORAX PAIN; URINARY TRACT INFECTION; URTICARIA;

ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERSENSITIVITY; HYPERSENSITIVITY, DELAYED; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SYNCOPE, VASOVAGAL;

EID: 77949544786     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/NAN.0b013e3181cfd36d     Document Type: Review

References (44)

1. Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007;17(2):210-218.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313): 1221-1231.
3. Behan PO, Chaudhuri A, Roep BO. The pathogenesis of multiple sclerosis revisited. J R Coll Physicians Edinb. 2002;32:244-265.
4. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13):938-952.
5. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338(5):278-285.
6. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci. 2007;256(suppl 1):S5-S13.
7. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4): 907-911.
8. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169-178.
9. AVONEX® (Interferon beta-1a) IM Injection [package insert]. Cambridge, MA: BIOGEN IDEC Inc; 2006.
10. COPAXONE® (glatiramer acetate injection) [package insert]. Kansas City, MO: TEVA Neuroscience, Inc.; 2007.
11. Rebif® (interferon beta-1a) SC injection [package insert]. Rockland, MA: EMD Serono, Inc.; 2008.
12. BETASERON® (Interferon beta-1b) for SC injection [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals Inc; 2008.
13. EXTAVIA (Inteferon beta-1b) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.
14. Baumhackl U. The search for a balance between short and longterm treatment outcomes in multiple sclerosis. J Neurol. 2008; 255(suppl 1):75-83.
15. Ebers GC, Hommes O, Hughes RAC, et al. Randomised doubleblind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498- 1504.
16. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000; 343(13):898-904.
17. NOVANTRONE® (mitoxantrone) for injection concentrate [package insert]. Rockland, MA: EMD Serono, Inc.; 2007.
18. Morrissey SP, Le Page E, Edan G. Mitoxantrone in the treatment of multiple sclerosis. Int MS J. 2005;12(3):74-87.
19. Rose JW, Foley J, Carlson N. Monoclonal antibody treatments for multiple sclerosis. Curr Neurol Neurosci Rep. 2008;8(5):419-426.
20. TYSABRI® (natalizumab) injection for intravenous use [package insert]. South San Francisco, CA: Elan Pharmaceuticals, Inc; 2008.
21. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
22. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
23. Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J Emerg Med. 2006;30(1):41-44.
24. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97(6):1408-1414.
25. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19-31.
26. RITUXAN® (rituximab) injection for intravenous use [package insert]. South San Francisco, CA: Genentech, Inc.; 2008.
27. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135(2):147.
28. Mohr DC, Goodkin DE, Likosky W, et al. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult Scler. 1996; 2(5):222-226.
29. Girouard N, Theoret G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs. 2008;30(4):18-25.
30. Ross AP. Tolerability, adherence, and patient outcomes. Neurology. 2008;71(24)(suppl 3):S21-S23.
31. O'Leary S, Beavin J, Bishop C, Capolino L, Greinel E, Hudson E. Practical guidelines for administering natalizumab: a nursing perspective. Int J MS Care. 2007;9:1-8.
32. Infusion Nurses Society. Policies and Procedures for Infusion Nursing. 3rd ed. Norwood, MA: Infusion Nurses Society; 2006.
33. Waters W, Brawner J, Winter T. MS Center of Atlanta Adverse Event Protocol. 2007.
34. Lenz H-J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5):601-609.
35. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis. J Allergy Clin Immunol. 1998;101(6, pt 2):S465-S528.
36. Update on the emergency medical treatment of anaphylactic reactions for first medical responders and for community nurses. Resuscitation. 2001;48(3):241-243.
37. Roujeau J-C, Stern RS, Wintroub BU. Cutaneous drug reactions. In: Fauci AS, Braunwald E, Kasper DL, et al., eds. Harrison's Principles of Internal Medicine. 17th ed. New York: McGraw Hill Medical; 2008:343-349.
38. Volcheck GW. Clinical evaluation and management of drug hypersensitivity. Immunol Allergy Clin North Am. 2004;24(3):357- 371, v.
39. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kumpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64(9):1331-1333.
40. Hellwig K, Schimrigk S, Fischer M, et al. Allergic and nonallergic delayed infusion reactions during natalizumab therapy. Arch Neurol. 2008;65(5):656-658.
41. Bloomfield DM. Strategy for the management of vasovagal syncope. Drugs Aging. 2002;19(3):179-202.
42. Gobel BH. Hypersensitivity reactions to biological drugs. Semin Oncol Nurs. 2007;23(3):191-200.
43. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391-1403.
44. Biogen Idec. The TYSABRI TOUCH® prescribing program. http://www.tysabri.com/tysbProject/tysb.portal/-baseurl/ twoColLayout/ SCSRepository/en-US/tysb/home/touch-prescribing/ index.xml. Accessed November 3, 2008.